At a glance
- Originator Aventis
- Class Antihypertensives; Heart failure therapies
- Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 09 Feb 2000 No-Development-Reported for Hypertension in USA (Unknown route)
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 06 Mar 1997 Preclinical development for Hypertension in USA (Unknown route)